4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

04 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

15 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

09 Nov 2023 15:19:53 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

01 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

12 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

07 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights

09 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

29 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data

17 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

07 Jun 2023 15:10:17 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

24 May 2023 07:00:01 By Nasdaq GlobeNewswire

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

10 May 2023 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 May 2023 15:05:01 By Nasdaq GlobeNewswire